Medication info

Acyclovir Tablets 200 mg (Acyclovir)

Prescription medicationTabletIntravenous injectionExpired
Ingredient · strength
Acyclovir›200mg / 1 tablet
Manufacturer / importer
Korea Sintax Pharmaceutical Co., Ltd.
Appearance
Light blue round tablets
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Expired

MFDS item code 202000309 · Approved 2020.01.20

This product's status changed to Expired on 2025.01.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment and prevention of herpes simplex (including genital herpes), treatment of herpes zoster, and treatment of chickenpox in children
Who receives it
Adults · Children
Adult administration
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer 200 mg of acyclovir per dose 5 times daily at 4-hour intervals for 5 days. For severe initial infections, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg or the route of administration may be changed to intravenous injection. 3) Treatment should be started as soon as possible after infection; for recurrent infections, it is preferable to start treatment at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in immunocompetent patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, patients receiving long-term treatment should periodically stop treatment for assessment every 6 ~ 12 months. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg per dose 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) In patients with severe immunocompromise or gastrointestinal malabsorption, intravenous administration should be considered. 3) Treatment should be started as soon as possible after infection; the earlier the treatment, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; use caution, for example by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the accumulation resulting from intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer 200 mg of this medicine every 12 hours. 2. Treatment of herpes zoster virus infections 1) For patients with creatinine clearance less than 10 mL/min, it is preferable to reduce the dose to 800 mg per dose twice daily, at approximately 12-hour intervals. 2) For patients with creatinine clearance of 10 ~ 25 mL/min, it is preferable to reduce the dose to 800 mg per dose 3 times daily, at approximately 8-hour intervals.
Child administration
○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients 1) Age 2 years and older: Same as the adult dose. 2) Under 2 years: Administer 1/2 of the adult dose. 3) There are currently no definitive data on the prevention of herpes simplex virus infections in immunocompetent patients. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset.

Ingredients

Manufacturer
Korea Sintax Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes simplex (including genital herpes), treatment of herpes zoster, and treatment of chickenpox in children

  • Genital herpes
  • herpes simplex virus infections of the skin and mucous membrane
  • herpes zoster virus infection
  • acute pain
  • chickenpox
View approved original text

This medication is used to treat and prevent infections of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes. It is also effective in the treatment of herpes zoster virus infections, particularly aiding in the relief of acute pain. However, its effectiveness in postherpetic neuralgia has not yet been proven. This medication is also used for the treatment of chickenpox in children aged two years and older. Overall, this medication is effective for treating various viral infections and alleviating acute symptoms.

How it is given

Adult administration

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer 200 mg of acyclovir per dose 5 times daily at 4-hour intervals for 5 days. For severe initial infections, treatment may be extended. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg or the route of administration may be changed to intravenous injection. 3) Treatment should be started as soon as possible after infection; for recurrent infections, it is preferable to start treatment at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in immunocompetent patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, patients receiving long-term treatment should periodically stop treatment for assessment every 6 ~ 12 months. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunocompromise (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose per administration may be increased to 400 mg or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg per dose 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) In patients with severe immunocompromise or gastrointestinal malabsorption, intravenous administration should be considered. 3) Treatment should be started as soon as possible after infection; the earlier the treatment, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; use caution, for example by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the accumulation resulting from intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer 200 mg of this medicine every 12 hours. 2. Treatment of herpes zoster virus infections 1) For patients with creatinine clearance less than 10 mL/min, it is preferable to reduce the dose to 800 mg per dose twice daily, at approximately 12-hour intervals. 2) For patients with creatinine clearance of 10 ~ 25 mL/min, it is preferable to reduce the dose to 800 mg per dose 3 times daily, at approximately 8-hour intervals.

Child administration

○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in immunocompromised patients 1) Age 2 years and older: Same as the adult dose. 2) Under 2 years: Administer 1/2 of the adult dose. 3) There are currently no definitive data on the prevention of herpes simplex virus infections in immunocompetent patients. 2. Treatment of chickenpox in children aged 2 years and older: Administer 20 mg per kg of body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset.

Precautions

This medication should not be used by patients with known allergies to this medication or its components, or to valacyclovir. Patients with impaired kidney function should use this medication with caution as neurological symptoms may occur. Patients with decreased liver function should use this medication carefully as it may further worsen liver function. This medication should be used cautiously in infants and young children, especially in newborns and low-birth-weight infants where safety has not been established, and should only be used when absolutely necessary. Elderly patients may have reduced kidney function which can increase blood concentration of this medication, potentially leading to increased adverse reactions; therefore, dosage and administration intervals should be adjusted and used with caution. During treatment with this medication, allergic reactions or skin rashes, fever, urticaria, blisters, etc., may occur. If such symptoms develop, discontinue use immediately and consult a physician. Rarely, serious allergic reactions such as shock or anaphylaxis may occur; if symptoms such as low blood pressure, difficulty breathing, or chest tightness appear, discontinue administration immediately and seek appropriate treatment. Neurological symptoms such as altered consciousness, confusion, hallucinations, convulsions, drowsiness, and anxiety may occur, especially more frequently in elderly patients and those with renal impairment. In patients with kidney issues, renal-related symptoms such as renal failure, hematuria, and proteinuria may present, necessitating caution. Liver-related side effects such as liver dysfunction, hepatitis, and jaundice may occur, so regular liver function tests are recommended. Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain may arise; consult a physician if symptoms are severe. Adequate hydration is essential during treatment with this medication; especially with high-dose administration, ensure to drink plenty of water to prevent dehydration and reduce renal toxicity. For the treatment of herpes simplex and chickenpox, the medication should be taken for 5 days; for shingles, for 7 days, and if symptoms do not improve, a change in therapy is advisable. Patients with weakened immune systems may consider intravenous treatment. Pregnant women or those who may become pregnant should use this medication only when absolutely necessary considering potential risks to the fetus, and breastfeeding mothers should discontinue nursing during the treatment period as this medication can be passed into breast milk. This medication may interact with other drugs, especially those affecting kidney function, or with theophylline, cimetidine, probenecid, or mycophenolate mofetil, so exercise caution when co-administering. In cases of overdose, serious symptoms such as coma, seizures, and mental confusion may occur, requiring immediate medical treatment, and if necessary, blood dialysis may be performed to reduce drug concentration. During treatment, caution is advised when driving or operating dangerous machinery as cognitive impairment may occur. Overall, this medication should be used carefully considering kidney and liver function state, and it is vital to consult a physician immediately if side effects or adverse symptoms arise.

Side effects

  • Anaphylactic shock
  • anaphylactic-like reaction
  • hypotension
  • dyspnea
  • chest tightness
  • photosensitivity reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 118 more
  • urticaria-like erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • impaired concentration
  • aggressive behavior
  • depersonalization
  • anxiety
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • seizures
  • drowsiness
  • tremors
  • agitation
  • forgetfulness
  • insomnia
  • anxiety
  • soliloquy
  • abnormal sensations
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • dizziness
  • renal failure
  • crystalluria
  • elevated BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • red blood cell casts in urine
  • pus in urine
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • hemorrhage
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • loose stools
  • upper abdominal pain
  • gastric pain
  • abdominal pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • fatigue
  • generalized malaise
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glycosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • hair loss
  • sweating
  • hyponatremia
  • hypoproteinemia
  • elevated total cholesterol levels
  • elevated triglyceride levels
  • elevated serum potassium levels
  • decreased serum albumin levels
  • anxiety
  • coma
  • seizures
  • somnolence
  • confusion
  • hallucinations
  • agitation
  • seizure disorders
  • comatose state

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Recommended storage temperature is between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Light blue round tablets

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.